Castle Biosciences will present TissueCypher Barrett’s Esophagus test data at DDW 2025, emphasizing risk stratification and personalized patient management. Castle Biosciences, Inc. will present new ...
Castle Biosciences’ TissueCypher® test can offer patients with Barrett’s esophagus a clearer picture of their risk of developing esophageal cancer. Esophageal cancer is a killer. It’s the eighth most ...
Castle Biosciences (CSTL) announced that it has received assay approval from the New York State Department of Health NYSDOH for its TissueCypher Barrett’s Esophagus test. TissueCypher is the first ...
Castle’s ongoing exploratory study is investigating the potential for developing a test that would complement DecisionDx-UM and provide a minimally invasive solution to identify lesions with ...
TissueCypher is Castle’s precision medicine risk-stratification test that predicts a patient’s individual risk of progression from Barrett’s esophagus (BE) to esophageal cancer FRIENDSWOOD, ...
The Operation Castle group of tests sought to validate dropping new, high-yield thermonuclear weapons from the air. However, the technology involved in making the bombs was complex and unproven, so ...
If you’ve been diagnosed with invasive melanoma, you probably have a lot of questions. The first one may be, “What happens next?” “The first thing we’re going to do is gather all the information we ...
Achieve near-complete or complete skin clearance, as reflected by a Validated Investigator Global Assessment score of clear (vIGA-AD 0, 36.4% vs 0%, p=0.006) Report higher rates of “no itch” (45.5% vs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results